A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.

Trial Details

NCT ID
NCT05463263
Phase
PHASE1 / PHASE2
Sponsor
Step Pharma, SAS
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • STP938
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Sarasota, Florida, United States|27.33643,-82.53065
  • New York, New York, United States|40.71427,-74.00597
  • Paris, Paris, France|48.85341,2.3488
  • Lyon, France|45.74906,4.84789

Key Eligibility Criteria

  • Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization.
  • Male or female aged ≥ 18 years.
  • Relapsed/refractory patients with histologically confirmed diagnosis of B cell or T cell lymphoma
  • Must have received at least 2 prior systemic therapies and have no treatment options known to provide clinical benefit

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →